Clinical trials: Diabetes Type 2
Type 2 Diabetes
Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)
This long term, placebo-controlled trial is intended to assess the efficacy and safety of exenatide, dosed twice a day, in Japanese patients with Type 2 Diabetes who are treated with oral antidiabetic(s) but not well controlled.
- Trial name
- NCT00577824
- Testing
- exenatide
- Where
- 12 sites in Japan
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as monotherapy in patients with type 2 diabetes mellitus and to assess baseline characteristics of patients with type 2 diabetes mellitus…
- Trial name
- NCT01650259
- Testing
- OAD, Trazenta
- Where
- Japan
- Volunteers
- 4,876 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.
- Trial name
- NCT00232583
- Testing
- Metformin, Insulin, Metfomin
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
Study D5553C00002 is a multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 3 study to compare the safety and efficacy of exenatide once weekly (EQW) added to titrated basal insulin glargine with or…
- Trial name
- NCT02229383
- Testing
- Exenatide
- Where
- 123 sites in United States, Hungary and 4 more
- Volunteers
- 464 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
My Diabetes Care: A Scalability and Usability Study
The purpose of this study is to conduct a prospective, longitudinal study on the My Diabetes Care (MDC) mobile intervention to assess usage patterns, user experience, and to uncover errors in functionality prior to a larger…
- Trial name
- NCT05448105
- Testing
- My Diabetes Care (MDC)
- Where
- 2 sites in United States
- Volunteers
- 67 people
- Sponsor
- Vanderbilt University Medical Center
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodium glucose co-transporter-2 inhibitor (SGLT-2i)…
- Trial name
- SUSTAIN 9 (NCT03086330)
- Testing
- Semaglutide
- Where
- 72 sites in United States, Austria and 5 more
- Volunteers
- 302 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy and safety of two different formulations of insulin degludec (IDeg) in subjects with type 2 diabetes.
- Trial name
- BEGIN™ (NCT01364428)
- Testing
- insulin degludec
- Where
- 45 sites in United States
- Volunteers
- 373 people
- Sponsor
- Novo Nordisk A/S
Glycemic Control
Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy of 2 doses of TAK-875 (25 mg and 50 mg), once daily (QD), plus metformin compared to placebo plus metformin and sitagliptin plus metformin on lowering blood sugar.
- Trial name
- NCT01549964
- Testing
- Fasiglifam (TAK-875), Sitagliptin
- Where
- 160 sites in United States, Australia and 9 more
- Volunteers
- 916 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin
This study will assess safety and efficacy of exenatide in combination with a thiazolidinedione (TZD) and a TZD plus metformin over 26 weeks in adult patients with type 2 diabetes who have not achieved adequate glycemic control.
- Trial name
- NCT00603239
- Testing
- exenatide
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 165 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when added to glimepiride on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are…
- Trial name
- NCT01494987
- Testing
- Ranolazine, Glimepiride, Diet
- Where
- 140 sites in United States, Czechia and 10 more
- Volunteers
- 431 people
- Sponsor
- Gilead Sciences
Ischemic Heart Disease, Ischemic Stroke
Study to Compare 2 Doses of Polycap Versus Single Dose of Polycap With or Without Pottasium
This is a randomized double blind 2x2 factorial controlled trial to evaluate efficacy tolerability of low strength Polycap versus two doses of low strength Polycap in patients with stable cardiovascular disease in reducing blood…
- Conditions
- Ischemic Heart Disease, Ischemic Stroke, Peripheral Vascular Disease, Type 2 Diabetes Mellitus
- Trial name
- TIPSK (NCT01404078)
- Testing
- Single Dose Polycap, Double dose Polycap
- Volunteers
- 518 people
- Sponsor
- St. John's Research Institute
Type 2 Diabetes, Insulin Resistance
Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance
The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in…
- Conditions
- Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
- Trial name
- NCT00443755
- Testing
- metformin, pioglitazone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Type 2 Diabetes, Obesity
Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans
Obesity is a heightened state of inflammation in which production of cytokines and matrix metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin resistance.
- Trial name
- DOXY (NCT01375491)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
- Trial name
- NCT00838916
- Testing
- albiglutide, insulin glargine
- Where
- 337 sites in United States, Russia and 2 more
- Volunteers
- 779 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of…
- Trial name
- NCT00974090
- Testing
- Teneli / Teneli + SU
- Where
- Japan
- Volunteers
- 194 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 1
Tandem Freedom - Feasibility Trial 2
This feasibility study is a prospective, single arm study evaluating the Tandem Freedom system in adults with type 1 diabetes. Existing Control-IQ technology users will use Control-IQ technology at home for a one week run-in…
- Trial name
- NCT06834568
- Testing
- t:slim X2 insulin pump with Tandem Freedom Algorithm
- Where
- New Zealand
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.
Healthy, Type 2 Diabetes
Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes
GLP-1 is a hormone made by the body that promotes the production of insulin in response to GLP-1 is produced within the islets expressing prohormone convertase 1/3eating.
- Trial name
- NCT04466618
- Testing
- Saline, Exendin-9,39, Saline + Intralipid/Heparin
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Adrian Vella
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive…
- Trial name
- NCT00614055
- Testing
- insulin degludec/insulin aspart, insulin glargine, metformin
- Where
- 28 sites in France, Germany and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Ketosis Prone Diabetes, Diabetes Ketoacidosis
Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment
The study intends on enrolling 48 subjects with diabetes. Diabetic subjects that no longer need insulin will be randomly placed (like the flip of a coin) on a diabetes pill called metformin, a diabetes pill called sitagliptin or…
- Conditions
- Ketosis Prone Diabetes, Diabetes Ketoacidosis, Hyperglycemia
- Trial name
- NCT01099618
- Testing
- metformin, Sitagliptin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Dawn Smiley MD
Type 2 Diabetes Mellitus (T2DM)
Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin
To compare a therapeutic strategy combining vildagliptin+metformin + Basal Insulin versus SU+metformin + Basal Insulin on the incidence of hypoglycemic events over 24 weeks.
- Trial name
- ADDONIS (NCT01871558)
- Testing
- Vildagliptin, Metformin, sulfonylurea (SU)
- Where
- 19 sites in France
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.